Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of screening visit~* Diagnosis of Crohn's disease (CD) with a minimum duration of CD of at least 3 months~* Has draining perianal fistulae as a complication of CD, confirmed by magnetic resonance imaging (MRI) at screening~* Previously demonstrated an inadequate clinical response, loss of response to, or intolerance of at least 1 of the following agents (depending on current country treatment recommendations/guidelines):~  * Antibiotics AND/OR~ * Immunomodulators AND/OR~ * Tumor necrosis factor α (TNFα) Antagonist~* Is willing and able to undergo MRI per protocol requirements~* Is willing and able to undergo flexible sigmoidoscopy per protocol requirements~Key Exclusion Criteria:~* Presence of current rectovaginal anovaginal or enterovesicular fistulae~* Presence of ulcerative colitis (UC), indeterminate colitis, ischemic colitis, fulminant colitis, or toxic mega-colon~* History of total proctocolectomy, total colectomy, presence of ileostomy or colostomy, or likely requirement for surgery during the study~* Use of any prohibited concomitant medications as described in the study protocol~* Active tuberculosis (TB) or history of latent TB that has not been treated~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Filgotinib 200 mg (Type: EXPERIMENTAL): Filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks
- Filgotinib 100 mg (Type: EXPERIMENTAL): Filgotinib 100 mg + placebo to match filgotinib 200 mg for 24 weeks
- Placebo (Type: EXPERIMENTAL): Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).